Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934389 | 0.87 | GRIA2 (0.77) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL2930121 | 0.85 | GRIA2 (0.74) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL2934808 | 0.84 | GRIA2 (0.73) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL2930371 | 0.83 | GRIA2 (0.76) | GRIA2CYP1A2 | |
| SCHEMBL2928683 | 0.83 | GRIA2 (0.70) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL5185695 | 0.82 | GRIA2 (0.68) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL2932498 | 0.81 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL13297266 | 0.80 | GRIA2 (0.65) | GRIA2 | |
| SCHEMBL2936383 | 0.79 | GRIA2 (0.71) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL5197494 | 0.79 | GRIA2 (0.64) | GRIA2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786766-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | claimed |
| US-7741351-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-06-22 | — | — | US | claimed |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | claimed |
| EP-1786766-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | claimed |
| WO-2006015829-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | claimed |
| EP-1786766-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-7741351-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203218-A1 | Compounds Which Potentiate Glutamate Receptor And Uses Thereof In Medicine | GRIN1, GRM1, GLRA1 | GRIA2 27/4885CYP1A2 1874/4885CYP2C19 1756/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | GRIA2 43/4885CYP1A2 4876/4885CYP2C19 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.